Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Duncan, Jacque

Description

Summary

RST-001 is a gene therapy given as an injection into the eye.

Official Title

Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP)

Keywords

Advanced Retinitis Pigmentosa gene therapy optogenetics channelrhodopsin retina retinitis pigmentosa Retinitis RST-001

Eligibility

You can join if…

Open to people ages 18 years and up

Participants must meet all of the following criteria.

  1. Age >= 18 years
  2. Signed and dated written informed consent obtained from the patient.
  3. Ability to comply with testing and all protocol tests.

You CAN'T join if...

Any one of the following will exclude patients from being enrolled into the study:

  1. Unable or unwilling to meet requirements of the study;
  2. Participation in a clinical study (ocular or non-ocular) with an investigational drug, agent or therapy in the past six months

Locations

  • Univeristy of California, San Francisco- Dept. of Ophthalmology accepting new patients
    San Francisco California 94143 United States
  • Retina Foundation of the Southwest accepting new patients
    Dallas Texas 75231 United States

Lead Scientist

  • Duncan, Jacque
    Retinitis pigmentosa (RP) affects about 1 in 3,500 people worldwide. Age-related macular degeneration (AMD) affects as many as 1 in 4 people by the age of 75 and is the leading cause of blindness in people over age 50 in the United States. Both RP and AMD have a hereditary basis, and currently, there is no cure for either of these types of hereditary retinal degeneration.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Allergan
Links
Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.
ID
NCT02556736
Phase
Phase 1/2
Study Type
Interventional
Last Updated